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Abstract
Introduction: Most breast cancers that occur in women with germline BRCA1 mutations are estrogen receptor-
negative (ER-) and also typically lack expression of progesterone receptor (PR) and HER2 overexpression. We
undertook a study to assess the clinical factors that predict for an estrogen receptor positive (ER+) breast cancer in
BRCA1 mutation carriers and to characterize the pathologic features of these tumors.
Methods: Clinical characteristics of BRCA1 carriers with 58 ER+ and 114 ER- first invasive breast cancers were
compared. Pathologic features of BRCA1 ER+ cancers were compared to those of BRCA1 ER- cancers and to age-
matched ER+ sporadic cancers.
Results: BRCA1 carriers aged ≥ 50 at diagnosis of first invasive breast cancer were more likely to have an ER+
cancer compared to those aged < 50 (57% vs 29%, P = 0.005). ER+ BRCA1 cancers were less likely than ER- BRCA1
cancers to have “BRCA-associated” features such as high mitotic activity, geographic necrosis/fibrotic focus, and
pushing margins (RR 0.06, 0.22, 0.24; P < 0.001, 0.02, 0.03 respectively). When compared to sporadic ER+ cancers, ER
+ BRCA1 cancers were more often of invasive ductal type (RR 2.4, P = 0.03), with a high mitotic rate (RR 5.0, P =
0.006) and absent or mild lymphocytic infiltrate (RR 10.2, P = 0.04).
Conclusions: BRCA1 carriers who are older at first breast cancer diagnosis are more likely to have ER+ tumors than
younger BRCA1 carriers. These ER+ cancers appear pathologically “intermediate” between ER- BRCA1 cancers and ER
+ sporadic breast cancers raising the possibility that either some ER+ BRCA1 cancers are incidental or that there is
a unique mechanism by which these cancers develop.
Introduction
Most breast cancers that occur in women with germline
BRCA1 mutations are estrogen receptor-negative (ER-)
and typically lack expression of progesterone receptor
(PR) and human epidermal growth factor receptor
(HER) 2 overexpression (so-called ‘triple-negative’ breast
cancers) [1-8]. These BRCA1-associated ER-tumors are
most often high-grade invasive ductal carcinomas with a
high mitotic rate that frequently exhibit other character-
istic pathologic features including a prominent lympho-
cytic infiltrate, pushing or circumscribed margins, and
geographic areas of necrosis or a central fibrotic focus
[3,9,10]. In addition, these tumors often express ‘basal’
biomarkers and most cluster within the ‘basal-like’
group in gene expression profiling studies [7,11-13].
Although the combination of the triple-negative phe-
notype and the pathologic features described above have
come to be considered characteristic of BRCA1-asso-
ciated breast cancers, approximately 10 to 36% of breast
cancers that occur in BRCA1 mutation carriers (BRCA1
carriers) are, in fact, ER-positive (ER+) [4,6,8,14,15].
Relatively little is known about these BRCA1-associated
ER+ breast cancers or about the factors that predict for
the ER status of breast cancers that develop in these
women.
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gested that ER negativity is intrinsic to BRCA1 cancers
and reflects the cell of origin of these tumors [16]. Sup-
porting this theory, Hosey and colleagues [17] have
s h o w nt h a tt r a n s f e c t i o no ft h ew i l d - t y p eBRCA1 gene
into HCC1937 cells, an ER- breast cancer cell line
homozygous for the BRCA1 mutation, restores ER pro-
duction. Likewise, knockdown of BRCA1 expression in
the ER+ cell lines MCF-7 and T47D eliminates expres-
sion of ER. These investigators further showed that
BRCA1 protein regulates the synthesis of ER through
binding to the estrogen receptor-alpha gene promoter,
ESR1. Liu and colleagues [18] proposed that BRCA1
may actually be required in the differentiation of ER-
stem/progenitor cells to ER+ luminal cells. In prophylac-
tic mastectomy specimens from women with germline
BRCA1 mutations, breast tissue was found that appeared
to be histologically normal, yet displayed loss of hetero-
zygosity (LOH) for BRCA1 and was positive for the
expression of the cancer stem cell marker, ALDH1 and
negative for the expression of ER. This finding suggested
that loss of BRCA1 may result in the accumulation of
ER- breast stem cells, which are genetically unstable and
more likely to undergo carcinogenesis.
If, in fact, ER negativity is intrinsic to BRCA1 cancers,
this would raise the possibility that at least some BRCA1
ER+ cancers may be ‘incidental’,a n dn o tc a u s e db ya
complete loss of BRCA1 function in the cancer cells.
It has been reported that ER+ breast cancers may be
more common as BRCA1 carriers age [16]. If so, the fre-
quency with which these ER+ breast cancers are
encountered in clinical practice may increase as strate-
gies for both prevention and treatment of the more
common ER- breast cancers improve and mutation car-
riers live longer.
Given the paucity of information regarding ER+ breast
cancers in BRCA1 mutation carriers, we undertook a
study to: determine the clinical factors that predict for
ER+ breast cancers in this population; compare the
pathologic features of ER+ BRCA1-associated breast
cancers with those of ER- BRCA1-associated breast can-
cers; and perform a case-control analysis to compare the
pathologic features of ER+ BRCA1-associated breast
cancers with those of ER+ sporadic breast cancers.
Materials and methods
Patient selection
Women with germline BRCA1 mutations who devel-
oped a first invasive breast cancer between 1979 and
2008 were retrospectively identified through the Can-
cer Risk and Prevention Programs at Beth Israel
Deaconess Medical Center (BIDMC), Brigham and
Women’s Hospital/Dana-Farber Cancer Institute, and
North Shore Medical Center. We identified 172
women with BRCA1-associated first invasive breast
cancers (114 ER- and 58 ER+).
Among these 172 women, we were able to obtain
pathologic material (H & E-stained sections and/or par-
affin blocks) for 117 first invasive breast cancers (68 ER-
and 49 ER+). Pathologic material was not available for
cases diagnosed before 1986. For the case-control analy-
sis, sporadic ER+ cancers (controls) were identified
through the BIDMC tumor registry and consisted of
women with a first invasive ER+ breast cancer and no
family history of breast or ovarian cancer, matched on
age and year of diagnosis (within three years) to the
BRCA1 carriers with ER+ breast cancers (cases). Two
BRCA1-associated cancers with ‘low-positive’ ER status
were excluded from the case-control analysis because
appropriate controls could not be identified. Three con-
trols were identified for each mutation carrier except for
three cases for which only two controls could be identi-
fied, resulting in a data set of 47 cases and 138 matched
controls. Genetic testing records at BIDMC were
reviewed to exclude potential control patients who had
a positive test for a BRCA1 or BRCA2 mutation.
Data collection
Clinical characteristics of BRCA1 carriers were
abstracted from medical records, and included age at
diagnosis, menopausal status at diagnosis, hormone use
prior to diagnosis, Ashkenazi Jewish heritage, age at first
live birth, smoking history, and alcohol use prior to
diagnosis.
Pathology review
Histologic sections of BRCA1-associated ER- and
BRCA1-associated ER+ breast cancers were reviewed by
the study pathologists blinded to the ER status of the
tumor. Each cancer was scored for the following patho-
logic features: histologic type; Nottingham combined
histologic grade, with each of the three components of
grade (i.e., tubule formation, nuclear grade, and mitotic
rate) recorded separately; presence of geographic necro-
sis or fibrotic focus; extent of lymphocytic infiltrate; and
tumor margin characteristics (invasive or pushing). His-
tologic sections of the sporadic ER+ cancers were
reviewed by the study pathologists and also assessed for
each pathologic feature described above.
Information regarding ER status, assessed as part of
the routine clinical evaluation, was abstracted from
pathology reports. A biochemical method was used to
determine the ER status between 1979 and 1992, and
immunostaining was employed between 1993 and 2009.
When information regarding the ER status for BRCA1
tumors was missing from the pathology report or when
ER was reported as ‘weak’ or ‘faint’, paraffin blocks were
re-cut and sections were immunostained for ER (rabbit
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USA). Information regarding PR and HER2 status was
also recorded for BRCA1 and control cancers.
Statistical analysis
Analysis of the relation between ER status and clinical
or pathologic factors used logistic regression, and analy-
sis of the case-control study of ER+ BRCA1 and spora-
dic cancers used the conditional (matched) logistic
regression. Both single covariate and step-up logistic
regressions for multiple comparisons were performed,
with two-sided P values from the likelihood ratio test.
All continuous covariates were categorized as in the
tables and used as binary variables in the models, with
an additional binary variable for ‘unknown’ if the value
of a covariate was unknown for at least two patients in
each group (e.g. in ER+ and ER- patients). In reporting
the final step-up model for each dataset, the P value for
a covariate comes from the step at which it was added
and the estimated risk ratio (RR) comes from the final
step.
This study was approved by the institutional review
boards of Dana Farber/Harvard Cancer Center and
North Shore Medical Center.
Results
Relation between clinical factors and ER status of first
breast cancers in BRCA1 mutation carriers
Table 1 summarizes the clinical characteristics of the
172 BRCA1 carriers and the results of single covariate
logistic regression comparing these features between
women with ER- and ER+ first breast cancers. Of these
172 patients, 34% (58) developed an ER+ first breast
cancer. Two of these 58 cancers were ‘weak’ ER+ (with
1 to 10% of tumor cells showing ER expression). Of the
172 patients, 16.3% had ER measured using biochemical
methods and 83.7% had ER measured using
immunohistochemistry.
Age at breast cancer diagnosis was a significant pre-
dictor of ER status. The median age at breast cancer
diagnosis was 40 years for women with an ER- cancer
and 46 years for those with an ER+ cancer. Patients
aged 50 years or older at diagnosis were significantly
more likely to have an ER+ cancer compared with those
younger than 50 years of age (16 of 28 = 57% vs 42 of
144 = 29%, P = 0.005). Conversely, patients younger
than 40 years of age were significantly less likely to have
an ER+ breast cancer compared with those aged
40 years or older (16 of 70 = 23% vs. 42 of 104 = 41%,
P = 0.01).
In addition, pre-menopausal patients were significantly
more likely to develop an ER- cancer compared with
post-menopausal patients or those with unknown meno-
pausal status (P = 0.02). Although only 29% of the
breast cancers that developed in pre-menopausal BRCA1
carriers were ER+, 53% of the cancers in post-menopau-
sal women were ER+.
In multiple covariate analysis, no covariate added sig-
nificantly to the model after age 50 years or older was
included. Although none of the women younger than 40
years of age at diagnosis were post-menopausal and only
14% of the women aged 40 to 49 years were post-meno-
pausal, 21% of the women aged 50 years or older were
pre-menopausal. None of the other clinical factors,
including prior hormone use, Ashkenazi Jewish heritage,
age at first live birth, smoking or alcohol use, predicted
for ER status of the first breast cancer of these women.
Comparison of pathologic features of ER- BRCA1-
associated and ER+ BRCA1-associated breast cancers
Pathologic material was available for 49 of the 58 ER+
BRCA1 cancers and for 68 of the 114 ER- BRCA1 breast
cancers. The distribution of cancers by age group was
similar in the clinical and pathology data sets (Tables 1
and 2).
Table 2 compares the pathologic characteristics of the
ER+ and ER-BRCA1 cancers. In single covariate models,
ER+ BRCA1 cancers were found less often than ER-
BRCA1 c a n c e r st ob eo fp u r ei n v a s i v ed u c t a lt y p e( P <
0.001), to be histologic grade 3 (P < 0.001), to possess a
high mitotic rate (>10 mitoses per 10 high powered field
(HPF); P < 0.001), to have a moderate/marked lympho-
cytic infiltrate (P = 0.003), to have either geographic
necrosis or a fibrotic focus (P < 0.001) or to have push-
ing (or unknown) margins (P <0 . 0 0 1 ) .M o s to ft h e s e
differences remained significant even when limiting the
comparison to histologic grade 3 BRCA1 ER+ and ER-
cancers. In particular, grade 3 ER+ BRCA1 cancers less
often had a high mitotic rate (P < 0.001), geographic
necrosis/fibrotic focus (P = 0.002), or pushing/unknown
margins (P < 0.001).
In a step-up logistic model, pathologic variables signif-
icantly predictive of a lower likelihood of having an ER+
breast cancer were high mitotic activity (RR 0.06,
P < 0.001), geographic necrosis or fibrotic focus (RR
0.22, P = 0.02), and pushing/unknown margins (RR 0.24,
P = 0.03). Of note, only 4% of ER+ BRCA1 breast can-
cers possessed all three of these features and 67% lacked
all three features (compared with 50% and 3%, respec-
tively, of ER- BRCA1 breast cancers). PR and HER2 sta-
tus were collected for the BRCA1 breast cancers and are
shown in Table 3.
Case-control analysis comparing pathologic features of
BRCA1-associated ER+ breast cancers with ER+ sporadic
breast cancers
The pathologic features of the 47 ER+ BRCA1 cancers
and 138 ER+ sporadic cancers are shown in Table 4.
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cancers were more often of pure invasive ductal type
(P = 0.03), more often had a high mitotic rate (>10
mitoses per 10 HPF, P = 0.03) and demonstrated a
more limited spectrum of histologic types. In the step-
up conditional logistic regression models, three vari-
ables were significantly more associated with ER+
BRCA-1 associated cancers than with ER+ sporadic
controls: pure invasive ductal histology (RR 2.4,
P = 0.03), 10 or more mitoses per 10 HPF (RR 5.0,
P = 0.006), and absent or mild lymphocytic infiltrate
(RR 10.2, P =0 . 0 4 ) .
Comparison of PR and HER2 status between ER+
BRCA1 breast cancers and sporadic controls was not
possible due to the unavailability of data for many of
the controls.
Table 1 Clinical characteristics of women with ER-negative and ER-positive BRCA1-associated breast cancers
Covariates ER- ER+ Logistic likelihood ratio test P
n%N%
All 114 66 58 34
Menopausal status
Pre * 98 71 41 29 0.02
Post 15 47 17 53
Unknown 1 100 0 0
Age of breast cancer
Median (range) 40 (27-73) 46 (29-72)
<40 54 77 16 23 0.01
40-49 48 65 26 35 0.73
≥ 50 12 43 16 57 0.005
Prior HRT
Yes * 11 58 8 42 0.42
No 101 67 50 33
Unknown 2 100 0 0
Ashkenazi Jewish
Yes * 55 71 23 29 0.32
No 58 64 33 36
Unknown * 13 326 7
First live birth before breast cancer?
Yes * 86 65 46 35 0.57
No 28 72 11 28
Unknown 0 0 1 100
Age of first live birth (if before breast cancer)
Median (range) 27 (15-45) 27 (19-42)
≥ 27 * 47 67 23 33 0.44
<27 39 63 23 37
No or unknown live births before breast cancer * 28 70 12 30
Tobacco (pack years)
0* 64 66 33 34 0.33
>0 31 74 11 26
Unknown * 19 58 14 42
Alcohol
0-1 drinks/week * 65 68 30 32 0.75
>1 drinks/week 45 64 25 36
Unknown * 45 734 3
ER, estrogen receptor; HRT, hormone replacement therapy; -, negative; +, positive.
Percentages calculated by row
(*) indicates this level of the covariate was included in the single covariate model.
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breast cancers (21%) had undergone genetic testing at
BIDMC and none was found to have a BRCA1 or
BRCA2 mutation. Some of the other women with ER+
sporadic breast cancers may have undergone genetic
testing at other institutions, but that information was
not available.
Discussion
The results of this study suggest that BRCA1 carriers
who are older at the time of diagnosis of their first
invasive breast cancer are more likely to have an ER+
breast cancer than are BRCA1 carriers who are younger
at diagnosis. Menopausal status was also a predictor of
ER positivity, with ER+ breast cancers being more com-
mon in post-menopausal carriers. However, this differ-
ence was not significant in multiple covariate analysis,
perhaps because of the confounding between menopau-
sal status and age. In particular, only 14% of BRCA1 car-
riers younger than age 50 years in our study were post-
menopausal. As mutation carriers increasingly become
surgically menopausal at younger ages it will be
Table 2 Comparison of pathologic characteristics of ER-negative and ER-positive BRCA1-associated breast cancers




Invasive ductal only * 67 99 37 76 <0.001
Other 1 1 12 24




3* 66 97 20 41 <0.001
1-2 2 3 28 57
Unknown (combined with 1-2) 00 1 2
Mitotic activity
>10 mitoses per 10 HPF * 64 94 11 22 <0.001
0-10 mitoses per 10 HPF 4 6 37 76
Unknown 00 1 2
Margins
Invasive * 22 32 44 90 <0.001
Pushing 41 60 4 8
Unknown 57 1 2
Lymphocytic infiltrate
Moderate/marked * 20 29 3 6 0.003
None/mild 46 68 45 92
Unknown * 23 1 2
Geographic necrosis/fibrotic focus
Yes * 50 74 8 16 <0.001
No 15 22 39 80
Unknown * 34 2 4
Age of breast cancer
Median (range) 39.5 (28-73) 45 (29-72)
<40 34 50 15 31 0.03
40-49 27 40 20 41 0.91
≥ 50 7 10 14 29 0.01
ER, estrogen receptor; HPF, high-powered field; -, negative; +, positive.
Percentages calculated by column
(*) indicates this level of the covariate was included in the single covariate model
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and menopausal status for predicting ER status of the
breast cancers that develop in this population. Our data
are consistent with those of Foulkes and colleagues [16]
who also found an increase in ER+ breast cancers with
increasing age among BRCA1 mutation carriers. These
investigators noted that this increase in ER positivity
paralleled that seen in breast cancers that develop in
non-mutation carriers. They did not study the effect of
menopausal status on ER status of these cancers. The
observation that BRCA1 mutation carriers who are older
or post-menopausal at the time of diagnosis of breast
cancer are more likely to have an ER+ breast cancer
may help to define a population of BRCA1 mutation
carriers for whom estrogen-modifying agents will be
particularly effective.
Of the BRCA1 cancers in this series, 34% were ER+.
This is consistent with the 31% frequency of ER+
BRCA1 breast cancers recently reported in the retro-
spective series by Atchley and colleagues [8].
Our comparison of the pathologic features of ER+ and
ER- BRCA1 cancers revealed that the ER+ cancers less
often had features typically associated with BRCA1
cancers, such as high mitotic rate, pushing margins,
marked lymphocytic infiltrate, and geographic necrosis/
fibrotic focus. These differences were not due to differ-
ences in histologic grade, because most remained signifi-
cant when only high-grade ER+ and ER- cancers were
compared. Although previous studies have noted that
ER- BRCA1 cancers are more likely to be high-grade
invasive ductal carcinomas compared with ER+ BRCA1
cancers, this is the first report to our knowledge analyz-
ing the relation of ER status to other pathologic features
that have come to be considered to be BRCA-related.
The differences in pathologic features between ER+
and ER- BRCA1 cancers raise the possibility that at least
some BRCA1 ER+ cancers may be ‘incidental’, and not
caused by a complete loss of BRCA1 function in the
cancer cells. In order to address the issue of whether ER
+ BRCA1 cancers are more akin to sporadic ER+ breast
cancers than to ER- BRCA1 cancers, we performed a
case-control analysis in which the pathologic features of
t h e s et u m o r sw e r ec o m p a r e dw i t ht h o s eo fac o n t r o l
group of ER+ sporadic breast cancers. We found that
BRCA1-associated ER+ cancers had a much more lim-
ited distribution of histologic types and were signifi-
cantly more often pure invasive ductal carcinomas with
a high mitotic rate than ER+ sporadic cancers.
There are several possible explanations for our obser-
vation that the histopathology of ER+ BRCA1 breast
cancers differs significantly from both ER- BRCA1 can-
cers as well as ER+ sporadic breast cancers. First, it may
be that although some ER+ BRCA1 breast cancers
develop from complete loss of BRCA1 function, others
still have intact BRCA1 function resulting in tumors
that as a group have phenotypic features that are inter-
mediate between ER- BRCA1 and ER+ sporadic breast
cancers. The issue of whether ER+ BRCA1-associated
breast cancers demonstrate LOH for the wild-type (wt)
BRCA1 allele has been investigated. In this regard,
Manié and colleagues recently found 4 of 19 ER+
BRCA1-associated breast cancers did not show loss of
the wt BRCA1 allele [19]. King and colleagues [20]
demonstrated that 11 of 22 BRCA1-associated invasive
breast cancers did not show LOH for wt BRCA1;n o
mention of ER status was included in their study. The
results of these studies are difficult to compare because
of differences in patient populations and molecular
methodology. Nonetheless, taken together the results of
these two studies raise the possibility that not all
BRCA1-associated breast cancers exhibit complete loss
of BRCA1 function. However, the frequency of this phe-
nomenon, particularly for ER+ BRCA1 cancers, remains
to be more clearly defined.
It is also possible that no breast cancer that develops
in a BRCA1 mutation carrier is really ‘incidental’ or
sporadic, even if LOH of wt BRCA1 does not exist.
Table 3 PR and HER2 status of BRCA1-associated breast
cancers
ER- BRCA1 cancers ER+ BRCA1 cancers
n = 68 n = 49
PR positive 04 0
HER2 +* 0 3 (1 IHC, 2 FISH)
HER2 negative** 0 34
HER2 equivocal^ 0 2
HER2 unknown 0 1
PR weak positive^^ 26
HER2 +* 0 1 (IHC)
HER2 -** 2 4
HER2 unknown 0 1
PR negative 59 1
HER2 +* 3 (IHC) 0
HER2 -** 48 1
HER2 equivocal^ 1 (FISH) 0
HER2 unknown 7
PR unknown 72
HER2 -** 6 2
HER2 unknown 1 0
ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER, human
epidermal growth factor receptor; IHC, immunohistochemistry; PR,
progesterone receptor; -, negative; +, positive.
* HER2 positive: HER2:CEP17 ratio by FISH >2.2 or IHC 3+ (no FISH performed)
** HER2 negative: HER2:CEP17 ratio by FISH <1.8 or IHC <3+ (no FISH
performed)
^HER2 equivocal: HER2:CEP17 ratio by FISH 1.8 to 2.2
^^ Weak PR positive: 1 to 10% cells show nuclear staining for PR
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BRCA1 heterozygous state, has been shown to have
demonstrable effects on the breast tissue of BRCA1 car-
riers. Normal breast tissue from BRCA1 carriers has
been shown to grow abnormally in three-dimensional
mammosphere cultures (even though 75% of cells show
retention of BRCA1 heterozygosity) [21], and express
increased aromatase [22] compared with reduction
mammoplasty specimens from non-mutation carriers.
Likewise, MCF-7 cells with BRCA1 haploinsuffiency
demonstrate decreased efficiency in homologous recom-
bination [23]. Haploinsufficiency of BRCA1 may predis-
pose both to the development of breast cancer as well
a st oam o r el i m i t e dh i s t o p a t h o logic profile. Finally, if
loss of BRCA1 function does exist in the majority of ER
+ BRCA1 breast cancers, it is possible that ER+ and ER-
BRCA1 cancers originate from different cells of origin
(e.g. early progenitor cell vs stem cell) leading to
Table 4 Comparison of pathologic features of ER-positive BRCA1-associated breast cancers and ER-positive sporadic
breast cancers
Covariates BRCA1 + Sporadic
n % N % Logistic likelihood ratio test P
All 47 100 138 100
Mean age in years (range) 46 (29-72) 46 (29-72)
Histologic type
Invasive ductal only 35 74 78 57 0.03
All others 12 26 60 43
Mixed ductal/lobular 10 21 25 18
Lobular 1 2 12 9





3 18 38 34 25 0.10
2 15 32 69 50 0.39
1 13 28 35 25 0.69
Unknown 1200
Mitoses/10 HPF
>10 9 19 9 7 0.03
6-10 12 26 31 22 0.67
0-5 25 53 98 71 0.03
Unknown 1200
Margins
Invasive 43 91 134 97 0.12
Pushing 3 6 2 1 0.09
Unknown 1221
Lymphocytic infiltrate
Moderate/marked 2 4 17 12 0.08
None/mild 44 94 121 88
Unknown 1200
Geographic necrosis/fibrotic focus
Yes 7 15 9 7 0.09
No 38 81 129 93
Unknown 2400
ER, estrogen receptor; HPF, high powered field.
Percentages calculated by column
* Mixed ductal plus: mucinous (n = 4), invasive micropapillary (n = 2), invasive papillary (n = 1), tubular (n = 1)
+ tubular (n = 1)
++ tubular (n = 6), mucinous (n = 5), invasive micropapillary (n = 2), invasive cribriform (n = 1), mixed invasive
micropapillary/mucinous (n = 1)
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BRCA1-associated breast cancers is still being deter-
mined [24,25].
One of the strengths of this study is that the patholo-
gic features of all cancers in this study, both BRCA1 and
control, were reviewed by two dedicated breast patholo-
gists (SJS and LCC). It should be noted that more of the
BRCA1 ER- breast cancers identified were unavailable
for pathologic review. Although 34% of the cases in the
clinical analysis were ER+, 42% of the cancers reviewed
pathologically were ER+. Given the uniformity of many
of the pathologic features of the BRCA1 ER- breast can-
cers in this study, we think it is unlikely that this sub-
stantially affected the major findings of our study.
One potential limitation of the case-control study is
that BRCA1 and 2 genetic testing information was not
available for all of the women with sporadic cancers.
However, as BRCA1 and BRCA2 cancers comprise only
5 to 10% of all cancers and potential controls were
excluded if a family history of breast or ovarian cancer
was noted in the medical record, it seems very unlikely
that more than a few of the ‘control’ cases had germline
BRCA1 mutations. We intentionally chose controls from
the general hospital population rather than from those
who tested negative for BRCA mutations through the
genetic testing clinic. Thus, our group of controls is
more likely to represent sporadic breast cancers than
those identified through a genetic testing program,
many of whom may have inherited breast cancers,
although not through a germline BRCA1 or 2 mutation.
Conclusions
In conclusion, the results of this study indicate that
BRCA1 carriers who are older at the time of invasive
breast cancer diagnosis are more likely to have ER+
breast cancers than younger BRCA1 carriers. Further-
more, ER+ BRCA1 breast cancers appear to be pathologi-
cally ‘intermediate’ between ER- BRCA1 cancers and ER+
sporadic cancers, thus comprising a unique group. These
observations raise the possibility that either some of the
ER+ BRCA1 cancers are incidental (i.e. not BRCA1-
related), or that there is a unique mechanism by which
they develop. Given the availability of new and effective
therapies that exploit the defect in homologous recombi-
nation, which exists in BRCA1-related cancers such as
poly (ADP-ribose) polymerase (PARP) inhibitors [26] and
Cisplatin [27], it will become increasingly important to
determine whether the pathways leading to ER+ BRCA1
breast cancers are similar to those that result in ER-
BRCA1 cancers and whether these new therapies are
likely to be effective in ER+ BRCA1 cancers. Toward this
end, a detailed immunophenotypic and molecular analy-
sis of the ER+ BRCA1 cancers is currently underway.
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